Do you have Chronic, Congenital, or Cyclical Neutropenia?

NEW STUDY OPEN!

Neutropenia clinical study seeks volunteers

This is a Phase 1b clinical research study, or clinical trial. This study will help researchers learn more about the investigational study medicine, mavorixafor, and what impact it may have after one dose.

About the Study

Neutropenia is complex, marked by having a low number of neutrophils, a type of white blood cell.

The study medicine, mavorixafor, is in capsules taken by mouth. It is not an injection.

The study will determine if mavorixafor:

- Is well-tolerated
- Will increase neutrophil cell counts after one dose

Why Take Part?

- Neutropenia is a disease with few treatment options. More treatment options are needed.
- Earlier studies of other diseases showed increased neutrophil counts after one dose of the study drug.
- Clinical studies are required to make sure a medicine is safe and works before it is approved for use by the FDA.

Who Can Join the Study?

- Over the age of 12 years old
- Diagnosed with chronic idiopathic, cyclical, or congenital neutropenia
- May or may not be treated with a medicine known as growth factor (G-CSF)
- Meet Absolute Neutrophil Count (ANC) requirements
- There are other criteria to join the study. To learn more, visit ClinicalTrials.gov and search for NCT04154488

What Does the Study Involve?

Duration:
The study medicine is taken for 1 day, and any possible side effects are monitored for 30 days.

Cost:
There is no cost for people to participate in the study. Mavorixafor, travel, and lodging costs are covered by X4 Pharmaceuticals.

Study sponsor:
X4 Pharmaceuticals is conducting the study.

Study sites:
There are several study sites, and the study may involve home health care and virtual check-ups.

Talk to your doctor to find out if this study is an option for you.

Email
clinicaltrialinfo@x4pharma.com

Call
857-529-5779

SCN-002-02-09282021-v1.0